IL6R binds tocilizumab

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Interleukin-6 (IL-6) is a pleiotropic pro-inflammatory cytokine. Its deregulation is associated with chronic inflammation, and multifactorial auto-immune disorders (Kaur et al. 2020). Tocilizumab is an anti-IL-6 receptor monoclonal antibody (mAb) with immunosuppressive action for chronic autoimmune indications such as rheumatoid arthritis (Choy et al. 2002). China's National Health Commission has authorised its use to treat patients with serious COVID-19-induced lung damage (Luo et al. 2020, Zhang et al. 2020a,b). In a small, uncontrolled study, Xu et al. suggest tocilizumab might attenuate the "cytokine storm" seen in Covid-19 patients by resolving high levels of IL6 and other proinflammatory cytokines (Xu et al. 2020).

Literature References
PubMed ID Title Journal Year
12483717 Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

Choy, EH, Isenberg, DA, Garrood, T, Farrow, S, Ioannou, Y, Bird, H, Cheung, N, Williams, B, Hazleman, B, Price, R, Yoshizaki, K, Nishimoto, N, Kishimoto, T, Panayi, GS

Arthritis Rheum. 2002
Participant Of
Cite Us!